Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.62 |
| ▸ | CNR1 | P21554 | 8/20 | 0.62 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SI | P14410 | 1/20 | 0.35 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6520138 | 0.90 | CNR2 (0.77) | CNR2CNR1MGAMGAASI | |
| SCHEMBL6526786 | 0.79 | CNR2 (0.61) | CNR2CNR1DPP4DPP8DPP9 | |
| SCHEMBL4934621 | 0.79 | CNR2 (0.80) | CNR2CNR1MGAMGAASI | |
| SCHEMBL2774342 | 0.77 | CNR2 (0.61) | CNR2CNR1MGAMGAASI | |
| SCHEMBL2771943 | 0.77 | CNR2 (0.61) | CNR2CNR1MGAMGAASI | |
| SCHEMBL2774400 | 0.76 | CNR2 (1.00) | CNR2CNR1MGAMGAASI | |
| SCHEMBL1927934 | 0.76 | CNR2 (0.84) | CNR2CNR1MGAMGAASI | |
| Hydrochloric Acid SCHEMBL6521926 | 0.76 | CNR2 (0.98) | CNR2CNR1MGAMGAASI | |
| SCHEMBL2774825 | 0.74 | CNR2 (0.78) | CNR2CNR1MGAMGAASI | |
| SCHEMBL23573214 | 0.74 | ALDH1A1 (0.40) | CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1675836-B1 | DERIVATIVES OF 4-PHENYLTHIAZOLES AND THE USE THEREOF AS MEDICAMENTS FOR TREATING NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY | IPSEN PHARMA (FR) | 2016-04-13 | — | — | EP | disclosed |
| US-20080108683-A1 | 4-PHENYLTHIAZOLE AND 4-PHENYLIMIDIZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20070054900-A1 | 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108683-A1 | 4-PHENYLTHIAZOLE AND 4-PHENYLIMIDIZOLE DERIVATIVES AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES, PAIN AND EPILEPSY | TPMT, MAPT, TRPV4 | CNR2 166/4885CNR1 294/4885DPP4 8/4885 |
| US-20070054900-A1 | 4-Phenlthiazole and 4-phenylimidizole derivatives and their use as medicaments for the treatment of neurodegenerative diseases, pain and epilepsy | TPMT, P2RX4, CACNA1I | CNR2 109/4885CNR1 202/4885DPP4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.